Literature DB >> 23597494

Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis.

Matthew B Harms1, Janet Cady, Craig Zaidman, Paul Cooper, Taha Bali, Peggy Allred, Carlos Cruchaga, Michael Baughn, Ryan T Libby, Alan Pestronk, Alison Goate, John Ravits, Robert H Baloh.   

Abstract

Hexanucleotide repeat expansions in C9ORF72 are a common cause of familial and apparently sporadic amyotrophic lateral sclerosis (ALS) and frontal temporal dementia (FTD). The mechanism by which expansions cause neurodegeneration is unknown, but current evidence supports both loss-of-function and gain-of-function mechanisms. We used pooled next-generation sequencing of the C9ORF72 gene in 389 ALS patients to look for traditional loss-of-function mutations. Although rare variants were identified, none were likely to be pathogenic, suggesting that mutations other than the repeat expansion are not a common cause of ALS, and providing supportive evidence for a gain-of-function mechanism. We also show by repeat-primed PCR genotyping that the C9ORF72 expansion frequency varies by geographical region within the United States, with an unexpectedly high frequency in the Mid-West. Finally we also show evidence of somatic instability of the expansion size by Southern blot, with the largest expansions occurring in brain tissue.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23597494      PMCID: PMC3679344          DOI: 10.1016/j.neurobiolaging.2013.03.006

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  35 in total

1.  The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.

Authors:  Javier Simón-Sánchez; Elise G P Dopper; Petra E Cohn-Hokke; Renate K Hukema; Nayia Nicolaou; Harro Seelaar; J Roos A de Graaf; Inge de Koning; Natasja M van Schoor; Dorly J H Deeg; Marion Smits; Joost Raaphorst; Leonard H van den Berg; Helenius J Schelhaas; Christine E M De Die-Smulders; Danielle Majoor-Krakauer; Annemieke J M Rozemuller; Rob Willemsen; Yolande A L Pijnenburg; Peter Heutink; John C van Swieten
Journal:  Brain       Date:  2012-02-01       Impact factor: 13.501

2.  Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.

Authors:  Adriano Chiò; Giuseppe Borghero; Gabriella Restagno; Gabriele Mora; Carsten Drepper; Bryan J Traynor; Michael Sendtner; Maura Brunetti; Irene Ossola; Andrea Calvo; Maura Pugliatti; Maria Alessandra Sotgiu; Maria Rita Murru; Maria Giovanna Marrosu; Francesco Marrosu; Kalliopi Marinou; Jessica Mandrioli; Patrizia Sola; Claudia Caponnetto; Gianluigi Mancardi; Paola Mandich; Vincenzo La Bella; Rossella Spataro; Amelia Conte; Maria Rosaria Monsurrò; Gioacchino Tedeschi; Fabrizio Pisano; Ilaria Bartolomei; Fabrizio Salvi; Giuseppe Lauria Pinter; Isabella Simone; Giancarlo Logroscino; Antonio Gambardella; Aldo Quattrone; Christian Lunetta; Paolo Volanti; Marcella Zollino; Silvana Penco; Stefania Battistini; Alan E Renton; Elisa Majounie; Yevgeniya Abramzon; Francesca Luisa Conforti; Fabio Giannini; Massimo Corbo; Mario Sabatelli
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

3.  C9ORF72 hexanucleotide repeat expansions in patients with ALS from the Coriell Cell Repository.

Authors:  Nicola J Rutherford; Mariely DeJesus-Hernandez; Matt C Baker; Thomas B Kryston; Patricia E Brown; Catherine Lomen-Hoerth; Kevin Boylan; Zbigniew K Wszolek; Rosa Rademakers
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

4.  C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population.

Authors:  Mario Sabatelli; Francesca Luisa Conforti; Marcella Zollino; Gabriele Mora; Maria Rosaria Monsurrò; Paolo Volanti; Kalliopi Marinou; Fabrizio Salvi; Massimo Corbo; Fabio Giannini; Stefania Battistini; Silvana Penco; Christian Lunetta; Aldo Quattrone; Antonio Gambardella; Giancarlo Logroscino; Isabella Simone; Ilaria Bartolomei; Fabrizio Pisano; Gioacchino Tedeschi; Amelia Conte; Rossella Spataro; Vincenzo La Bella; Claudia Caponnetto; Gianluigi Mancardi; Paola Mandich; Patrizia Sola; Jessica Mandrioli; Alan E Renton; Elisa Majounie; Yevgeniya Abramzon; Francesco Marrosu; Maria Giovanna Marrosu; Maria Rita Murru; Maria Alessandra Sotgiu; Maura Pugliatti; Carmelo Rodolico; Cristina Moglia; Andrea Calvo; Irene Ossola; Maura Brunetti; Bryan J Traynor; Giuseppe Borghero; Gabriella Restagno; Adriano Chiò
Journal:  Neurobiol Aging       Date:  2012-03-13       Impact factor: 4.673

5.  Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p.

Authors:  Heather Stewart; Nicola J Rutherford; Hannah Briemberg; Charles Krieger; Neil Cashman; Marife Fabros; Matt Baker; Alice Fok; Mariely DeJesus-Hernandez; Andrew Eisen; Rosa Rademakers; Ian R A Mackenzie
Journal:  Acta Neuropathol       Date:  2012-01-07       Impact factor: 17.088

6.  Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer's disease.

Authors:  Sara Rollinson; Nicola Halliwell; Kate Young; Janis Bennion Callister; Greg Toulson; Linda Gibbons; Yvonne S Davidson; Andrew C Robinson; Alex Gerhard; Anna Richardson; David Neary; Julie Snowden; David M A Mann; Stuart M Pickering-Brown
Journal:  Neurobiol Aging       Date:  2012-03-10       Impact factor: 4.673

7.  High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients.

Authors:  Kin Y Mok; Georgios Koutsis; Lucia V Schottlaender; James Polke; Marios Panas; Henry Houlden
Journal:  Neurobiol Aging       Date:  2012-03-22       Impact factor: 4.673

8.  Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study.

Authors:  Susan Byrne; Marwa Elamin; Peter Bede; Aleksey Shatunov; Cathal Walsh; Bernie Corr; Mark Heverin; Norah Jordan; Kevin Kenna; Catherine Lynch; Russell L McLaughlin; Parameswaran Mahadeva Iyer; Caoimhe O'Brien; Julie Phukan; Brona Wynne; Arun L Bokde; Daniel G Bradley; Niall Pender; Ammar Al-Chalabi; Orla Hardiman
Journal:  Lancet Neurol       Date:  2012-02-03       Impact factor: 44.182

9.  Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.

Authors:  Elisa Majounie; Alan E Renton; Kin Mok; Elise G P Dopper; Adrian Waite; Sara Rollinson; Adriano Chiò; Gabriella Restagno; Nayia Nicolaou; Javier Simon-Sanchez; John C van Swieten; Yevgeniya Abramzon; Janel O Johnson; Michael Sendtner; Roger Pamphlett; Richard W Orrell; Simon Mead; Katie C Sidle; Henry Houlden; Jonathan D Rohrer; Karen E Morrison; Hardev Pall; Kevin Talbot; Olaf Ansorge; Dena G Hernandez; Sampath Arepalli; Mario Sabatelli; Gabriele Mora; Massimo Corbo; Fabio Giannini; Andrea Calvo; Elisabet Englund; Giuseppe Borghero; Gian Luca Floris; Anne M Remes; Hannu Laaksovirta; Leo McCluskey; John Q Trojanowski; Vivianna M Van Deerlin; Gerard D Schellenberg; Michael A Nalls; Vivian E Drory; Chin-Song Lu; Tu-Hsueh Yeh; Hiroyuki Ishiura; Yuji Takahashi; Shoji Tsuji; Isabelle Le Ber; Alexis Brice; Carsten Drepper; Nigel Williams; Janine Kirby; Pamela Shaw; John Hardy; Pentti J Tienari; Peter Heutink; Huw R Morris; Stuart Pickering-Brown; Bryan J Traynor
Journal:  Lancet Neurol       Date:  2012-03-09       Impact factor: 44.182

10.  Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.

Authors:  Johnathan Cooper-Knock; Christopher Hewitt; J Robin Highley; Alice Brockington; Antonio Milano; Somai Man; Joanne Martindale; Judith Hartley; Theresa Walsh; Catherine Gelsthorpe; Lynne Baxter; Gillian Forster; Melanie Fox; Joanna Bury; Kin Mok; Christopher J McDermott; Bryan J Traynor; Janine Kirby; Stephen B Wharton; Paul G Ince; John Hardy; Pamela J Shaw
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

View more
  31 in total

Review 1.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 2.  C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity.

Authors:  Jennifer S Yokoyama; Daniel W Sirkis; Bruce L Miller
Journal:  Am J Neurodegener Dis       Date:  2014-03-28

Review 3.  There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS.

Authors:  Aaron D Gitler; Hitomi Tsuiji
Journal:  Brain Res       Date:  2016-04-06       Impact factor: 3.252

Review 4.  The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease.

Authors:  Aaron R Haeusler; Christopher J Donnelly; Jeffrey D Rothstein
Journal:  Nat Rev Neurosci       Date:  2016-05-06       Impact factor: 34.870

5.  Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms.

Authors:  Carlos Cruchaga; Jorge L Del-Aguila; Benjamin Saef; Kathleen Black; Maria Victoria Fernandez; John Budde; Laura Ibanez; Yuetiva Deming; Manav Kapoor; Giuseppe Tosto; Richard P Mayeux; David M Holtzman; Anne M Fagan; John C Morris; Randall J Bateman; Alison M Goate; Oscar Harari
Journal:  Alzheimers Dement       Date:  2017-09-21       Impact factor: 21.566

Review 6.  RNA-mediated toxicity in C9orf72 ALS and FTD.

Authors:  Zachary T McEachin; Janani Parameswaran; Nisha Raj; Gary J Bassell; Jie Jiang
Journal:  Neurobiol Dis       Date:  2020-08-21       Impact factor: 5.996

Review 7.  From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.

Authors:  Aziza Rashed Alrafiah
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

8.  Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.

Authors:  Janet Cady; Peggy Allred; Taha Bali; Alan Pestronk; Alison Goate; Timothy M Miller; Robi D Mitra; John Ravits; Matthew B Harms; Robert H Baloh
Journal:  Ann Neurol       Date:  2014-11-27       Impact factor: 10.422

Review 9.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

10.  C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

Authors:  Elaine Y Liu; Jenny Russ; Kathryn Wu; Donald Neal; Eunran Suh; Anna G McNally; David J Irwin; Vivianna M Van Deerlin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2014-05-08       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.